[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Ebola Virus Vaccine Market & Pipeline Insight

September 2014 | 80 pages | ID: E7A0DD86D75EN
Kuick Research

US$ 1,500.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Ebola virus infection, which was previously called Ebola hemorrhagic fever, was discovered in 1976. The infection caused due to Ebola virus originates from four different strains of Ebola virus. These viruses generally are known to affect non-human primates, and are transmitted from wild animals to the humans and among the latter, it is known to spread through human-to-human transmission. The natural hosts of Ebola virus are Fruit bats, which belong to the Pteropodidae family.

Ebola virus is mostly found among primates in the African region, (mainly in the remote villages of Central and West Africa, near tropical rainforests) and in the Philippines. Other than Africa, this infection has been observed in regions like Republic of Congo, Gabon, Sudan, Ivory Coast and Uganda.

In terms of treatment, till date, there is not standard treatment method for Ebola hemorrhagic fever. Only supportive therapy is available. Also, there is no licensed vaccine for Ebola virus infection which is of clinical use. The researchers have been trying to better understand this virus and target its ecological reservoirs in order to get a deeper understanding of the cause and nature of the outbreaks of this disease. There are currently many experiments in the laboratories which are focusing on developing an appropriate vaccine for the prevention of this disease, but no success has been met till now.

The pharma companies have a significant opportunity in the field of Ebola virus infections in terms of developing drugs, vaccines and introducing measures to control and prevent the spread of the disease. After the success of the clinical candidates, and the market approval of these drugs or vaccines, it is most likely that there could a significant demand for these products from the physicians and patients. Additionally, due to the nature of the disease, these products would be priced at a premium, which would eventually yield high revenues for the companies which would earn a significant return on investment.

“Ebola Virus Vaccine Market & Pipeline Insight” Report Highlight:
  • Ebola Virus Infection Market Overview
  • Ebola Vaccine Clinical Trial Insight by Phase, Company & Country
  • Ebola Vaccine in Clinical Trials: 26 Vaccine
  • Majority Ebola Vaccine in Preclinical Phase: 15 Vaccines
  • Ebola Vaccines by Mechanism of Action, Drug Class, Route of administration, Patent Analysis & Licensing Status

1. EBOLA VIRUS INFECTION MARKET OVERVIEW

1.1 Symptoms & Diagnostics
1.2 Causes of Ebola Virus Infection
1.3 Incidence
1.4 Ongoing developments
1.5 Future Scenario

2. EBOLA VACCINE CLINICAL TRIAL OVERVIEW

3. EBOLA VACCINE CLINICAL TRIAL INSIGHT BY PHASE, COMPANY & COUNTRY

3.1 Research
3.2 Preclinical
3.3 Clinical
3.4 Phase-I

4. SUSPENDED & DISCONTINUED EBOLA VACCINE CLINICAL TRIAL INSIGHT BY PHASE, COMPANY & COUNTRY

4.1 No Development Reported
4.2 Discontinued
4.3 Suspended

5. COMPETITIVE LANDSCAPE

5.1 Bavarian Nordic
5.2 Crucell
5.3 Fab Entech
5.4 Inovio Pharmaceuticals
5.5 Microbiotix
5.6 Mitsubishi Tanabe Pharma
5.7 Profectus Biosciences
5.8 SIGA Technologies
5.9 Tekmira Pharmaceuticals
5.10 Vaxart

LIST OF FIGURES

Figure 1-1: Ebola Incidence & Deaths, October’2014
Figure 2-1: Ebola Vaccine Clinical Trial by Phase (%), 2014
Figure 2-2: Ebola Vaccine Clinical Trial by Phase (Number), 2014
Figure 2-3: Suspended & Discontinued Ebola Vaccine in Clinical Trial by Phase (%), 2014
Figure 2-4: Suspended & Discontinued Ebola Vaccine in Clinical Trial by Phase (Number), 2014

LIST OF TABLES

Table 1-1: Ebola Incidence Since 1976


More Publications